Class information for:
Level 1: ERCC1//RRM1//MED OVARIAN CANC SECT

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
13007 866 38.9 90%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
6 4 GASTROENTEROLOGY & HEPATOLOGY//ONCOLOGY//SURGERY 1371034
216 3       NON SMALL CELL LUNG CANCER//LUNG CANCER//THORAC SURG 51214
1422 2             XRCC1//GEMCITABINE//ERCC1 7962
13007 1                   ERCC1//RRM1//MED OVARIAN CANC SECT 866

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 ERCC1 authKW 5845025 31% 61% 271
2 RRM1 authKW 1269280 6% 67% 54
3 MED OVARIAN CANC SECT address 417532 2% 79% 15
4 EXCISION REPAIR CROSS COMPLEMENTATION GROUP 1 authKW 392436 2% 70% 16
5 EXCISION REPAIR CROSS COMPLEMENTATION 1 authKW 215958 1% 88% 7
6 EXCISION REPAIR CROSS COMPLEMENTATION GROUP 1 ERCC1 authKW 181329 1% 86% 6
7 XPF authKW 152541 2% 29% 15
8 ERCC1 PROTEIN HUMAN authKW 141035 0% 100% 4
9 TXR1 authKW 141035 0% 100% 4
10 EXCISION REPAIR CROSS COMPLEMENTING GROUP 1 authKW 141031 1% 67% 6

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Oncology 15583 68% 0% 592
2 Respiratory System 1112 10% 0% 85
3 Genetics & Heredity 219 8% 0% 69
4 Pathology 159 5% 0% 39
5 Pharmacology & Pharmacy 116 9% 0% 81
6 Medicine, Research & Experimental 95 5% 0% 44
7 Cell Biology 32 5% 0% 46
8 Biotechnology & Applied Microbiology 24 4% 0% 33
9 Toxicology 21 2% 0% 20
10 Biochemistry & Molecular Biology 19 9% 0% 78

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 MED OVARIAN CANC SECT 417532 2% 79% 15
2 INSERM CANC POPULAT ER3 70518 0% 100% 2
3 UMR S981 70518 0% 100% 2
4 PROGRAM THORAC ONCOL 70514 0% 50% 4
5 PATHOL 5442 52885 0% 50% 3
6 BIOSTAT PUBL HLTH INNOVAT DECIS SUPPORT PO 47010 0% 67% 2
7 MED BRANCHNIH 47010 0% 67% 2
8 CATALAN ONCOL 41045 3% 4% 26
9 ABORAT INNOVAT CANC MEDSTATE KEY LA 35259 0% 100% 1
10 AFFILATED RENMIN HOSP 35259 0% 100% 1

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 LUNG CANCER 12710 5% 1% 40
2 JOURNAL OF THORACIC ONCOLOGY 8204 3% 1% 25
3 CLINICAL LUNG CANCER 4626 1% 1% 10
4 PHARMACOGENOMICS 3343 2% 1% 13
5 GENETICS AND MOLECULAR RESEARCH 2789 3% 0% 23
6 TUMOR BIOLOGY 2746 3% 0% 22
7 CLINICAL CANCER RESEARCH 2242 4% 0% 31
8 CANCER CHEMOTHERAPY AND PHARMACOLOGY 2088 2% 0% 21
9 ANNALS OF ONCOLOGY 2043 3% 0% 22
10 ASIAN PACIFIC JOURNAL OF CANCER PREVENTION 2010 2% 0% 18

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 ERCC1 5845025 31% 61% 271 Search ERCC1 Search ERCC1
2 RRM1 1269280 6% 67% 54 Search RRM1 Search RRM1
3 EXCISION REPAIR CROSS COMPLEMENTATION GROUP 1 392436 2% 70% 16 Search EXCISION+REPAIR+CROSS+COMPLEMENTATION+GROUP+1 Search EXCISION+REPAIR+CROSS+COMPLEMENTATION+GROUP+1
4 EXCISION REPAIR CROSS COMPLEMENTATION 1 215958 1% 88% 7 Search EXCISION+REPAIR+CROSS+COMPLEMENTATION+1 Search EXCISION+REPAIR+CROSS+COMPLEMENTATION+1
5 EXCISION REPAIR CROSS COMPLEMENTATION GROUP 1 ERCC1 181329 1% 86% 6 Search EXCISION+REPAIR+CROSS+COMPLEMENTATION+GROUP+1+ERCC1 Search EXCISION+REPAIR+CROSS+COMPLEMENTATION+GROUP+1+ERCC1
6 XPF 152541 2% 29% 15 Search XPF Search XPF
7 ERCC1 PROTEIN HUMAN 141035 0% 100% 4 Search ERCC1+PROTEIN+HUMAN Search ERCC1+PROTEIN+HUMAN
8 TXR1 141035 0% 100% 4 Search TXR1 Search TXR1
9 EXCISION REPAIR CROSS COMPLEMENTING GROUP 1 141031 1% 67% 6 Search EXCISION+REPAIR+CROSS+COMPLEMENTING+GROUP+1 Search EXCISION+REPAIR+CROSS+COMPLEMENTING+GROUP+1
10 PLATINUM BASED CHEMOTHERAPY 135987 3% 15% 25 Search PLATINUM+BASED+CHEMOTHERAPY Search PLATINUM+BASED+CHEMOTHERAPY

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 MACERELLI, M , GANZINELLI, M , GOUEDARD, C , BROGGINI, M , GARASSINO, MC , LINARDOU, H , DAMIA, G , WIESMULLER, L , (2016) CAN THE RESPONSE TO A PLATINUM-BASED THERAPY BE PREDICTED BY THE DNA REPAIR STATUS IN NON-SMALL CELL LUNG CANCER?.CANCER TREATMENT REVIEWS. VOL. 48. ISSUE . P. 8 -19 99 63% 2
2 AMABLE, L , (2016) CISPLATIN RESISTANCE AND OPPORTUNITIES FOR PRECISION MEDICINE.PHARMACOLOGICAL RESEARCH. VOL. 106. ISSUE . P. 27 -36 54 38% 11
3 FRIBOULET, L , OLAUSSEN, KA , PIGNON, JP , SHEPHERD, FA , TSAO, MS , GRAZIANO, S , KRATZKE, R , DOUILLARD, JY , SEYMOUR, L , PIRKER, R , ET AL (2013) ERCC1 ISOFORM EXPRESSION AND DNA REPAIR IN NON-SMALL-CELL LUNG CANCER.NEW ENGLAND JOURNAL OF MEDICINE. VOL. 368. ISSUE 12. P. 1101 -1110 26 76% 126
4 HAN, YL , LIU, J , SUN, ML , ZHANG, ZP , LIU, CY , SUN, YP , (2016) A SIGNIFICANT STATISTICAL ADVANCEMENT ON THE PREDICTIVE VALUES OF ERCC1 POLYMORPHISMS FOR CLINICAL OUTCOMES OF PLATINUM-BASED CHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER: AN UPDATED META-ANALYSIS.DISEASE MARKERS. VOL. . ISSUE . P. - 33 83% 0
5 TISEO, M , BORDI, P , BORTESI, B , BONI, L , BONI, C , BALDINI, E , GROSSI, F , RECCHIA, F , ZANELLI, F , FONTANINI, G , ET AL (2013) ERCC1/BRCA1 EXPRESSION AND GENE POLYMORPHISMS AS PROGNOSTIC AND PREDICTIVE FACTORS IN ADVANCED NSCLC TREATED WITH OR WITHOUT CISPLATIN.BRITISH JOURNAL OF CANCER. VOL. 108. ISSUE 8. P. 1695-1703 31 72% 42
6 YANG, YL , XIAN, L , (2014) THE ASSOCIATION BETWEEN THE ERCC1/2 POLYMORPHISMS AND THE CLINICAL OUTCOMES OF THE PLATINUM-BASED CHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER (NSCLC): A SYSTEMATIC REVIEW AND META-ANALYSIS.TUMOR BIOLOGY. VOL. 35. ISSUE 4. P. 2905 -2921 37 61% 13
7 JIANG, JW , LIANG, XH , ZHOU, XL , HUANG, RF , CHU, ZH , ZHAN, Q , (2012) ERCC1 EXPRESSION AS A PROGNOSTIC AND PREDICTIVE FACTOR IN PATIENTS WITH NON-SMALL CELL LUNG CANCER: A META-ANALYSIS.MOLECULAR BIOLOGY REPORTS. VOL. 39. ISSUE 6. P. 6933-6942 30 77% 27
8 BARSANTI-INNES, B , HEY, SP , KIMMELMAN, J , (2017) THE CHALLENGES OF VALIDATING IN PRECISION MEDICINE: THE CASE OF EXCISION REPAIR CROSS-COMPLEMENT GROUP 1 DIAGNOSTIC TESTING.ONCOLOGIST. VOL. 22. ISSUE 1. P. 89 -96 36 63% 0
9 VASSALOU, H , STATHOPOULOS, E , FIOLITAKI, G , KOUTSOPOULOS, A , VOUTSINA, A , GEORGOULIAS, V , MAVROUDIS, D , (2013) EXCISION-REPAIR-CROSS-COMPLEMENT-1 PROTEIN AS A PROGNOSTIC FACTOR IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER TREATED WITH PLATINUM-BASED FIRST-LINE CHEMOTHERAPY.LUNG CANCER. VOL. 82. ISSUE 2. P. 324-329 30 77% 8
10 LEE, SM , FALZON, M , BLACKHALL, F , SPICER, J , NICOLSON, M , CHAUDHURI, A , MIDDLETON, G , AHMED, S , HICKS, J , CROSSE, B , ET AL (2017) RANDOMIZED PROSPECTIVE BIOMARKER TRIAL OF ERCC1 FOR COMPARING PLATINUM AND NONPLATINUM THERAPY IN ADVANCED NON-SMALL-CELL LUNG CANCER: ERCC1 TRIAL (ET).JOURNAL OF CLINICAL ONCOLOGY. VOL. 35. ISSUE 4. P. 402 -+ 21 64% 1

Classes with closest relation at Level 1


Rank Class id link
1 8721 THYMIDYLATE SYNTHASE//DIHYDROPYRIMIDINE DEHYDROGENASE//OROTATE PHOSPHORIBOSYLTRANSFERASE
2 2272 XRCC1//XRCC3//XPD
3 8385 GEMCITABINE//DEOXYCYTIDINE KINASE//HENT1
4 22399 LUNG CANCER DIAGNOSIS AND PROGNOSIS//AIRWAY EPITHELIUM DEVELOPMENT//ANAT CYTOL PATHOL ALBERT BONNIOT
5 14457 CISPLATIN RESISTANCE//RAT OVARIAN TUMOR CELL LINES//TCRP1
6 10628 EPOTHILONES//IXABEPILONE//PATUPILONE
7 601 XERODERMA PIGMENTOSUM//COCKAYNE SYNDROME//NUCLEOTIDE EXCISION REPAIR
8 37603 HLTH IMPROVING//BIOMED ENGN NANOSCI TRANSLAT NANOMED//CANCER CHERNOTHERAPY
9 147 GEFITINIB//EGFR MUTATION//ERLOTINIB
10 22701 PEMETREXED//MULTITARGETED ANTIFOLATE//AFFILIATED JIANGSU CANC HOSP

Go to start page